Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Parthenon Therapeutics

Request full access

Inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment

Cambridge, United StatesFounded 2019Biotech & Life Sciences

About Parthenon Therapeutics

Parthenon Therapeutics is a startup that operates in the biotechnology industry, focusing on the development of therapeutics. The company is led by Wendye, a seasoned entrepreneur with a track record of building successful companies from scratch and raising over $1 billion in public and private markets. She has been instrumental in the development of various therapeutics, including Qutenza™, Ajovy™, and others in the pipeline.

Parthenon Therapeutics' business model revolves around the development and commercialization of therapeutics. The company collaborates with investors and other companies to raise funds, develop therapeutics, and bring them to market. Once the therapeutics are developed, they are sold to larger pharmaceutical companies or brought to market by Parthenon Therapeutics itself. The company's revenue is generated from the sale of these therapeutics.

The company's clients are primarily large pharmaceutical companies interested in acquiring new therapeutics. However, Parthenon Therapeutics also works with investors who provide the necessary funding for the development of these therapeutics.

The company's Chief Medical Officer, Dr. Joseph Paul Eder, brings over 30 years of clinical experience from leading cancer research institutions and the pharmaceutical industry. His expertise further strengthens the company's ability to develop effective therapeutics.

In summary, Parthenon Therapeutics is a biotechnology startup that develops therapeutics and brings them to market, either by selling them to larger pharmaceutical companies or commercializing them itself. The company is led by experienced professionals and operates in a high-growth market.

Source: Dealroom company data

At a glance

Status
Operational
Employees
24
Open positions
None listed
Dealroom signal
61.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Nov 2021 $65M $260M Section 32 · KdT Ventures · Park West Asset Management · Breakout Ventures —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Parthenon Therapeutics website traffic

Latest recorded traffic for Parthenon Therapeutics is 1.5K monthly website visits, down 28.6% over the last three months. Parthenon Therapeutics's team declined 22.6% over the past year.

Latest monthly visits1.5K 3-month web change-28.6% 1-year team growth-22.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Parthenon Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Parthenon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Northpond Ventures
  • Taiho Ventures
  • Section 32
  • KdT Ventures
  • Park West Asset Management
  • Breakout Ventures
  • Alexandria Equities
  • Pfizer Ventures
  • Creacion Ventures
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States95.8%
🇦🇺 Australia4.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Parthenon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Parthenon Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.